Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

N/AActive Not RecruitingNCT05633771

Sandoz562 enrolled

Overview

An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.

The main purpose of this non-interventional study is to assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation in Inflammatory Bowel Disease (IBD) patients. Primary data will be collected at each data collection time point (visits will be according to local clinical practice). Data will be collected based on the information reported in the medical records. This study does not impose a therapy protocol, procedure or change in routine medical practice. Apart from self-administered questionnaires, no additional examinations or assessments are required, consequently there are no additional medical risks for the patients. The total duration of the study will be 36 months (3 years). The recruitment period will be for 2 years with individual patient follow-up for up to 1 year. It is expected that patients will visit their physicians at regular intervals depending on local specific clinical practices. Four time points for data collection will be defined: * T0 (patient inclusion in the study and Baseline characteristics). * T1 (3-month follow-up ± 1 month). * T2 (6-month follow-up and primary criteria -2/+3 months). * T3 (12-month follow-up -3/+2 months).

Study Type

OBSERVATIONAL

Enrollment

562

Conditions

Inflammatory Bowel Disease

Interventions

HyrimozOTHER

There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients must meet all of the following criteria at Baseline: * Patients initiating Hyrimoz® treatment. * Patients with a confirmed diagnosis (following local recommendations) of one of these indications: CD or UC. * Patients ≥ 18 years of age. * Patient in whom the decision to initiate Hyrimoz® (naïve population) or to switch (switch population) from reference adalimumab to Hyrimoz® was accorded with his physician before the proposal to participate in the study. * Patients meeting one of the following criteria: * Referred to as "switched patients": Patients treated continuously with adalimumab (other than Hyrimoz®) for at least 6 months, with an indication for continuing treatment with adalimumab at any therapeutic dose (physician's decision) and who have controlled stable disease for at least 3 months before study enrollment (according to the physician's criteria). * Referred to as "biologic-naive patients": Patients who had an inadequate response or contraindications to conventional therapy with no exposure to any biological medicine and targeted therapies and started Hyrimoz® as a first-line biologic therapy according to the summary of product characteristics (SmPC). * Patients able to complete and understand the self-administered questionnaires. * Patients who have been informed and have provided a signed written consent as per local regulations prior to participation in the study Exclusion Criteria: Patients fulfilling any of the following criteria are not eligible for inclusion in this study: * Patients enrolled in an ongoing interventional study. * Patients with any contraindications to Hyrimoz® according to the SmPC. * Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula). * Use of any investigational drug in last 6 months prior to enrollment. * Patient received any biological medicine or targeted therapy, in case of " biologic-naive patient ", * Patient received adalimumab for less than 6 months or have controlled disease for less than 3 months, in case of "switched patient".

Locations (51)

Outcomes

Primary Outcomes

Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation

Assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation

Time frame: Up to 6 months

Secondary Outcomes

Percentage of patients who discontinue Hyrimoz

Percentage of patients who discontinue Hyrimoz® at T2 and T3 due to: * Lack of efficacy. * Intolerance/Adverse event(s) or special scenario. * Patient's decision * Nocebo effect * Other reasons.

Time frame: 6 months, 12 months

Percentage of patients with high level of treatment satisfaction using TSQM-9 questionnaire

To assess patients' treatment satisfaction (based on 9-item Treatment Satisfaction Questionnaire for Medication \[TSQM 9\], the percentage of patients with high level of treatment satisfaction (score ≥ 39) will be collected. The TSQM-9 is declined with 9 questions about patient treatment satisfaction. Each answer gives a number of points depending of the question and the answer. The final score is the sum of points in each question. This questionnaire score from 9 to 59 points. In HYRISS study, we estimate that patient with \< 39 pts in TSQM-9 are considered with a low satisfaction for the medication (satisfaction under 60%).

Time frame: 3 months, 6 months, 12 months

Percentage of patients with high level of treatment adherence using adapted CQR5 questionnaire

To assess adherence/compliance to treatment (based on 5 item Compliance Questionnaire for Rheumatology \[CQR5\] adapted for gastroenterologist), percentage of patients with high level of treatment adherence (score ≥ 15) using adapted CQR5 questionnaire will be collected. The CQR5 is declined with 5 questions about patient compliance to the treatment. Each answer gives from 1 to 4 points depending of the answer. The final score is the sum of points in each question. This questionnaire score from 5 (very low compliance) to 20 points (very strong compliance).

Time frame: Baseline, 3 months, 6 months, 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.